Clinical Trial Update: Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for poziotinib in HER2+ metastatic breast cancer patients after at least two prior HER2-directed regimens.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Poziotinib (poziotinib)

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED